Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr. McFarland Webinar - May 29, 2021
View:
Post by Eoganacht on Apr 30, 2021 2:08pm

Dr. McFarland Webinar - May 29, 2021

Nanomaterials and Biomedical Applications Webinars

The webinars will be archived and can be viewed later through the Rebroadcast Platform

29 May 2021 - 9:00 PM - 10:00 PM EST
 
Abstract
 
Tackling Cancer and Infection with Light-Responsive Molecules
- Dr. Sherri A. McFarland
 
Photomedicine is an interdisciplinary field where chemistry and light meet to fight disease. Photodynamic therapy (PDT) is a special branch of photomedicine that employs a sensitizer molecule, light, and oxygen to destroy unwanted cells with spatiotemporal selectivity. Despite its enormous potential for treating certain diseases, including cancer and infection, PDT has yet to become mainstream. For over a decade, our research team has worked to bring new PDT technologies from bench to bedside. Using a multidisciplinary approach, we have introduced both synthetic compounds and natural products (both have successfully completed Phase 1 clinical trials and are currently in Phase 2) as alternatives to existing porphyrin-based PDT agents for specific indications. This seminar will share some of our experiences in developing metallodrug photosensitizers for treating bladder cancer and photoactive plant extracts for improving oral health.
Comment by fredgoodwinson on Apr 30, 2021 2:21pm
Thanks Eog - much look forward to viewing that when available.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250